secwatch.observer — SEC 8-K summary
======================================

Issuer:     Editas Medicine, Inc. (EDIT)
CIK:        0001650664
Form:       8-K
Filed at:   2023-02-22T23:59:59+00:00
Accession:  0001558370-23-001684
Event type: earnings
Sentiment:  neutral
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Editas Medicine reports Q4 2022 net loss $60.7M; advances EDIT-301 trials, sells iNK franchise to Shoreline
--------------------------------------------------------------------------------

- Q4 2022 net loss $60.7M ($0.88/share) vs $41.4M ($0.61) in Q4 2021; full year net loss $220.4M ($3.21).
- Cash $437.4M at Dec 31, 2022, down from $619.9M a year ago; expects to fund operations into 2025.
- EDIT-301 for SCD: parallel patient dosing started in RUBY trial; on track to dose 20 patients by year-end, clinical update by mid-2023.
- Entered definitive agreement to sell iNK cell franchise and license SLEEK/AsCas12a technologies to Shoreline Biosciences.
- BMS opted into three additional gene editing programs and declared one new development candidate under collaboration.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1650664/000155837023001684/0001558370-23-001684-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1650664/000155837023001684/edit-20230222x8k.htm
  HTML page:      https://secwatch.observer/filing/0001558370-23-001684

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer